Table 1.
Relationship of clinicopathological parameters to angiogenesis
| Parameter | VEGF | CD31‐MVD | CD34‐MVD | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Low | High | P‐value | Low | High | P‐value | Low | High | P‐value | |
| All patients | 7 | 30 | 16 | 21 | 12 | 25 | |||
| Age | |||||||||
| ≤65 years | 4 | 7 | 0.16 | 2 | 9 | 0.07 | 3 | 8 | 0.66 |
| >65 years | 3 | 23 | 14 | 12 | 9 | 17 | |||
| Gender | |||||||||
| Male | 3 | 22 | 0.18 | 13 | 11 | 0.09 | 10 | 15 | 0.26 |
| Female | 4 | 8 | 3 | 10 | 2 | 10 | |||
| Tumor size (mm) | |||||||||
| ≤30 | 3 | 13 | 0.98 | 7 | 10 | 0.82 | 4 | 12 | 0.49 |
| >30 | 4 | 17 | 9 | 11 | 8 | 13 | |||
| Histology | |||||||||
| Adenocarcinoma | 5 | 13 | 0.23 | 6 | 12 | 0.32 | 4 | 14 | 0.29 |
| Non‐adenocarcinoma | 2 | 17 | 10 | 9 | 8 | 11 | |||
| Disease stage (p‐stage) | |||||||||
| I | 4 | 16 | 0.86 | 9 | 11 | 0.82 | 4 | 15 | 0.17 |
| II + III | 3 | 14 | 7 | 10 | 8 | 10 | |||
| LAT1 | |||||||||
| Positive | 1 | 18 | 0.04 | 7 | 12 | 0.51 | 6 | 13 | 0.80 |
| Negative | 6 | 12 | 9 | 9 | 5 | 13 | |||
| Ki‐67 labeling index | |||||||||
| High | 3 | 27 | 0.01 | 13 | 18 | 0.72 | 10 | 21 | 0.96 |
| Low | 4 | 3 | 3 | 3 | 2 | 4 | |||
Abbreviation: Non‐adenocarcinoma, non‐small cell lung cancer except for adenocarcinoma; LAT1, L‐type amino acid transporter 1; VEGF, vascular endothelial growth factor; MVD, microvessel density.